Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
ArGEN-X
ArGEN-X
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
The (r)evolution of biocatalysis in API synthesis
Explore Farmhispania Group’s enzyme toolbox to develop cost-effective, green-by-design synthetic routes for the cGMP production of your small-molecule NCEs
From batch to continuous chemistry to continuous processing
The main challenge in many flow reactors lies in achieving a smooth and continuous flow within microchannels. Dec Group focuses on effectively transporting solid materials and...
PCI Pharma Services commences installation of sterile fill-finish and lyophilisation line
The Bedford, NH site will advance PCI's manufacturing capabilities with twin lyophilisers and a large-scale isolator filling line, making this the third sterile fill-finish...
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
arGEN-X and LEO Pharma sign deal to develop antibody-based treatments for skin conditions
Dutch biotechnology company could potentially receive nearly €105m in payments
Research & Development
arGEN-X awarded €1.5m grant from IWT in Flanders
To advance the application of NHance Fc modifications in therapeutic antibodies
Manufacturing
Lonza signs multi-product agreement with arGEN-X for therapeutic antibodies
Building on a four-year relationship between the two companies
Research & Development
Shire signs monoclonal antibody agreement with arGEN-X
Will make an upfront payment to arGEN-X of €15m
Research & Development
arGEN-X to collaborate with Bayer
To discover and develop therapeutic antibody candidates
Research & Development
ArGEN-X appoints Werner Lanthaler to its Supervisory Board
He has been Chief Executive of Evotec for the past five years
Research & Development
ArGEN-X appoints David Lacey to supervisory board
Former head of discovery research at Amgen joins the Dutch firm
Subscribe now